Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer

NCT03567720 is registered in ClinicalTrials.gov with OncoSec Medical Incorporated as lead sponsor.

NCT NCT03567720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03567720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer
Lead sponsor
OncoSec Medical Incorporated
Phase
Phase 2
Overall status
Unknown status
Start date
October 11, 2018
Completion date
September 30, 2024
Enrollment
65 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer